Literature DB >> 28057692

CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?

Diego Calvisi1, Robert Eferl2.   

Abstract

Entities:  

Keywords:  CELL CYCLE; HEPATOCELLULAR CARCINOMA; PHARMACOTHERAPY

Mesh：

Substances：

Year:  2017        PMID： 28057692     DOI： 10.1136/gutjnl-2016-313547

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  3 in total

1.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

2.  8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells.

Authors:  Ning Wang; Shaopeng Chen; Bin Zhang; Shangfu Li; Feng Jin; Dan Gao; Hongxia Liu; Yuyang Jiang
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

3.  CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.

Authors:  Yiran Chen; Li Li; Jie Lan; Yang Cui; Xiaosong Rao; Jing Zhao; Tao Xing; Gaoda Ju; Guangtao Song; Jizhong Lou; Jun Liang
Journal:  Mol Cancer       Date:  2022-01-04       Impact factor: 27.401
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.